← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
101	101 BioRestorative Therapies BRTX $2.02M	–	–	–	–
102	102 Cabaletta Bio CABA $263M	–	–	–	–
103	103 Candel Therapeutics CADL $682M	–	–	–	–
104	104 Caris Life Sciences CAI $8.98B	–	–	–	–
105	105 CAMP4 Therapeutics CAMP $216M	–	–	–	–
106	106 Celularity CELU $43.2M	–	–	–	–
107	107 Creative Medical Technology CELZ $6.21M	–	–	–	–
108	108 DELISTED CERo Therapeutics CERO	–	–	–	–
109	109 Calidi Biotherapeutics CLDI $2.25M	–	–	–	–
110	110 DELISTED Centogene N.V. Common Shares CNTG	–	–	–	–
111	111 Coya Therapeutics COYA $102M	–	–	–	–
112	112 Caribou Biosciences CRBU $49.8M	–	–	–	–
113	113 DELISTED CARGO Therapeutics CRGX	–	–	–	–
114	DBTX 114 DELISTED Decibel Therapeutics, Inc. Common Stock DBTX	–	–	–	–
115	115 Ginkgo Bioworks DNA $792M	–	–	–	–
116	116 Design Therapeutics DSGN $656M	–	–	–	–
117	117 Precision BioSciences DTIL $170M	–	–	–	–
118	118 enGene Therapeutics ENGN $115M	–	–	–	–
119	119 Estrella Immunopharma ESLA $23.3M	–	–	–	–
120	120 FibroBiologics FBLG $7.08M	–	–	–	–
121	121 4D Molecular Therapeutics FDMT $711M	–	–	–	–
122	FRLN 122 DELISTED Freeline Therapeutics Holdings plc American Depositary Shares FRLN	–	–	–	–
123	123 DELISTED Generation Bio GBIO	–	–	–	–
124	124 CytoMed Therapeutics GDTC $10.4M	–	–	–	–
125	125 Guardant Health GH $22.3B	–	–	–	–